Abivax shares dip as traders wait for late-Q2 Phase 3 maintenance data and M&A chatter cools

Abivax SA (ABVX) is down 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears driven more by positioning than by a fresh, company-specific announcement, with investors focused on an upcoming late-Q2 2026 Phase 3 maintenance-trial topline readout for obefazimod. This could also reflect profit-taking and fading takeover speculation after a period of elevated expectations.

Details:

Abivax recently reiterated that its pivotal Phase 3 ABTECT-UC maintenance trial remains on track to report topline results in late Q2 2026, keeping the stock highly sensitive to sentiment shifts ahead of the catalyst.

The company disclosed that a March 18, 2026 DSMB meeting found no new safety signals, based on an analysis including all randomized patients and with nearly 90% completing 44 weeks in the double-blind maintenance trial.

Abivax reported cash, cash equivalents, and short-term investments of €530.4 million as of December 31, 2025, with a projected cash runway into Q4 2027, which may reduce near-term financing concerns but does not eliminate binary trial risk.

Recent market discussion has centered on potential strategic interest and data-room access timelines; if no formal proposal materializes, speculative premium can compress quickly.

Sources:

Abivax Investor Relations, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABVX Hedge Fund Activity

We have seen 174 institutional investors add shares of $ABVX stock to their portfolio, and 73 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MORGAN STANLEY added 1,681,277 shares (+114.3%) to their portfolio in Q4 2025, for an estimated $226,728,609
WESTFIELD CAPITAL MANAGEMENT CO LP added 1,009,966 shares (+inf%) to their portfolio in Q4 2025, for an estimated $136,198,964
VESTAL POINT CAPITAL, LP added 900,000 shares (+90.0%) to their portfolio in Q4 2025, for an estimated $121,369,499
DEUTSCHE BANK AG\ added 764,899 shares (+inf%) to their portfolio in Q4 2025, for an estimated $103,150,454
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 720,222 shares (+2080.7%) to their portfolio in Q4 2025, for an estimated $97,125,537
FAIRMOUNT FUNDS MANAGEMENT LLC removed 713,434 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $96,210,142
CORMORANT ASSET MANAGEMENT, LP removed 600,000 shares (-30.8%) from their portfolio in Q4 2025, for an estimated $80,913,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/25/2026
Citizens issued a "Market Outperform" rating on 12/16/2025
Truist Securities issued a "Buy" rating on 11/24/2025
Wolfe Research issued a "Outperform" rating on 11/06/2025

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 8 analysts offer price targets for $ABVX in the last 6 months, with a median target of $146.5.

Here are some recent targets:

Etzer Darout from Barclays set a target price of $148.0 on 03/24/2026
Faisal Khurshid from Jefferies set a target price of $160.0 on 03/16/2026
Julian Harrison from BTIG set a target price of $150.0 on 02/25/2026
David Nierengarten from Wedbush set a target price of $110.0 on 02/24/2026
Judah Frommer from Morgan Stanley set a target price of $145.0 on 01/09/2026
Jason Butler from Citizens set a target price of $131.0 on 12/16/2025
Gregory Renza from Truist Securities set a target price of $140.0 on 11/24/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.